Amita Gupta1,2, Susan Swindells3, Soyeon Kim4, Michael D Hughes5, Linda Naini6, Xingye Wu5, Rodney Dawson7, Vidya Mave1,2, Jorge Sanchez8, Alberto Mendoza9, Pedro Gonzales8, Nagalingeswaran Kumarasamy10, Kyla Comins11, Francesca Conradie12, Justin Shenje13, Sandy Nerette Fontain14, Anthony Garcia-Prats15, Aida Asmelash16, Supalert Nedsuwan17, Lerato Mohapi18, Umesh G Lalloo19, Ana Cristina Garcia Ferreira20, Christopher Mugah21, Mark Harrington22, Lynne Jones4, Samyra R Cox1, Betsy Smith23, N Sarita Shah24, Anneke C Hesseling15, Gavin Churchyard25,26,27. 1. Johns Hopkins University, Department of Medicine, Baltimore, Maryland. 2. Byramjee Jeejeebhoy Government Medical College, Johns Hopkins University Clinical Research Site, Pune, India. 3. University of Nebraska Medical Center, Omaha. 4. Frontier Science & Technology Research Foundation, Amherst, New York. 5. Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 6. Social & Scientific Systems, Silver Spring, Maryland. 7. University of Cape Town Lung Institute and Department of Medicine, University of Cape Town, South Africa. 8. Asociación Civil Impacta Salud y Educación, Lima, Peru. 9. TASK Applied Science Clinical Research Site, Bellville, South Africa. 10. Chennai Antiviral Research and Treatment Clinical Research Site, India. 11. TASK Applied Science Clinical Research Site, Bellville. 12. University of the Witwatersrand Helen Joseph Hospital, Johannesburg, South Africa. 13. South African Tuberculosis Vaccine Initiative, Cape Town, South Africa. 14. GHESKIO Centers Institute of Infectious Diseases and Reproductive Health, Port-au-Prince, Haiti. 15. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa. 16. Gaborone Clinical Research Site, Botswana. 17. PHPT-Changrai Prachanukroh Hospital, Chiang Rai, Thailand. 18. Soweto Clinical Research Site, University of the Witwatersrand, Johannesburg, South Africa. 19. Durban International Clinical Research Site, Durban University of Technology, South Africa. 20. Instituto Nacional de Infectologia - INI/Fiocruz, Brazil. 21. Kenya Medical Research Institute, Kisumu. 22. Treatment Action Group, New York, New York. 23. National Institutes of Health, Bethesda, Maryland. 24. US Centers for Disease Control and Prevention, Atlanta, Georgia. 25. Aurum Institute, Parktown, South Africa. 26. University of Witwatersrand, School of Public Health. 27. Advancing Care and Treatment, South African Medical Research Council, Johannesburg, South Africa.
Abstract
BACKGROUND: We assessed multidrug-resistant tuberculosis (MDR-TB) cases and their household contacts (HHCs) to inform the development of an interventional clinical trial. METHODS: We conducted a cross-sectional study of adult MDR-TB cases and their HHCs in 8 countries with high TB burdens. HHCs underwent symptom screenings, chest radiographies, sputum TB bacteriologies, TB infection (TBI) testing (tuberculin skin test [TST] and interferon gamma release assay [IGRA]), and human immunodeficiency virus (HIV) testing. RESULTS: From October 2015 to April 2016, 1016 HHCs from 284 MDR-TB cases were enrolled. At diagnosis, 69% of MDR-TB cases were positive for acid-fast bacilli sputum smears and 43% had cavitary disease; at study entry, 35% remained smear positive after a median MDR-TB treatment duration of 8.8 weeks. There were 9 HHCs that were diagnosed with TB prior to entry and excluded. Of the remaining 1007 HHCs, 41% were male and the median age was 25 years. There were 121 (12%) HHCs that had new cases of TB identified: 17 (2%) were confirmed, 33 (3%) probable, and 71 (7%) possible TB cases. The TBI prevalence (defined as either TST or IGRA positivity) was 72% and varied by age, test used, and country. Of 1007 HHCs, 775 (77%) were considered high-risk per these mutually exclusive groups: 102 (10%) were aged <5 years; 63 (6%) were aged ≥5 and were infected with HIV; and 610 (61%) were aged ≥5 years, were negative for HIV or had an unknown HIV status, and were TBI positive. Only 21 (2%) HHCs were on preventive therapy. CONCLUSIONS: The majority of HHCs in these high-burden countries were at high risk of TB disease and infection, yet few were receiving routine preventive therapy. Trials of novel, preventive therapies are urgently needed to inform treatment policy and practice.
BACKGROUND: We assessed multidrug-resistant tuberculosis (MDR-TB) cases and their household contacts (HHCs) to inform the development of an interventional clinical trial. METHODS: We conducted a cross-sectional study of adult MDR-TB cases and their HHCs in 8 countries with high TB burdens. HHCs underwent symptom screenings, chest radiographies, sputum TB bacteriologies, TB infection (TBI) testing (tuberculin skin test [TST] and interferon gamma release assay [IGRA]), and human immunodeficiency virus (HIV) testing. RESULTS: From October 2015 to April 2016, 1016 HHCs from 284 MDR-TB cases were enrolled. At diagnosis, 69% of MDR-TB cases were positive for acid-fast bacilli sputum smears and 43% had cavitary disease; at study entry, 35% remained smear positive after a median MDR-TB treatment duration of 8.8 weeks. There were 9 HHCs that were diagnosed with TB prior to entry and excluded. Of the remaining 1007 HHCs, 41% were male and the median age was 25 years. There were 121 (12%) HHCs that had new cases of TB identified: 17 (2%) were confirmed, 33 (3%) probable, and 71 (7%) possible TB cases. The TBI prevalence (defined as either TST or IGRA positivity) was 72% and varied by age, test used, and country. Of 1007 HHCs, 775 (77%) were considered high-risk per these mutually exclusive groups: 102 (10%) were aged <5 years; 63 (6%) were aged ≥5 and were infected with HIV; and 610 (61%) were aged ≥5 years, were negative for HIV or had an unknown HIV status, and were TBI positive. Only 21 (2%) HHCs were on preventive therapy. CONCLUSIONS: The majority of HHCs in these high-burden countries were at high risk of TB disease and infection, yet few were receiving routine preventive therapy. Trials of novel, preventive therapies are urgently needed to inform treatment policy and practice.
Authors: V Vella; V Racalbuto; R Guerra; C Marra; A Moll; Z Mhlanga; M Maluleke; H Mhlope; B Margot; G Friedland; N S Shah; N R Gandhi Journal: Int J Tuberc Lung Dis Date: 2011-09 Impact factor: 2.373
Authors: N Sarita Shah; Courtney M Yuen; Moonseong Heo; Arielle W Tolman; Mercedes C Becerra Journal: Clin Infect Dis Date: 2013-09-24 Impact factor: 9.079
Authors: Razia Fatima; Ejaz Qadeer; Aashifa Yaqoob; Mahboob Ul Haq; Suman S Majumdar; Hemant D Shewade; Robert Stevens; Jacob Creswell; Nasir Mahmood; Ajay M V Kumar Journal: PLoS One Date: 2016-11-29 Impact factor: 3.240
Authors: Davit Baliashvili; Neel R Gandhi; Soyeon Kim; Michael Hughes; Vidya Mave; Alberto Mendoza-Ticona; Pedro Gonzales; Kim Narunsky; Poongulali Selvamuthu; Sharlaa Badal-Faesen; Caryn Upton; Linda Naini; Elizabeth Smith; Amita Gupta; Gavin Churchyard; Susan Swindells; Anneke Hesseling; N Sarita Shah Journal: Clin Infect Dis Date: 2021-09-15 Impact factor: 9.079
Authors: V Rouzier; M Murrill; S Kim; L Naini; J Shenje; E Mitchell; M Raesi; M Lourens; A Mendoza; F Conradie; N Suryavanshi; M Hughes; S Shah; G Churchyard; S Swindells; A Hesseling; A Gupta Journal: Int J Tuberc Lung Dis Date: 2022-10-01 Impact factor: 3.427